Table 1.
Full experimental details and results in the existing literature.
| Autor. | #Ν | Tools | Comparison | Results |
|---|---|---|---|---|
| Bechara et al. [9] | 30 | IPSS, IPSS-QoL, Qmax, PVR, GAQ, IIEF-EF, | TMS vs. TMS + TDF | No significant differences in Qmax and PVR. IIEF improvement with TMS + TDF. |
| Gacci et al. [10] | 60 | IPSS, IIEF-5, OAB-q, Qmax, Qave, RPV | TMS vs. TMS + VRF vs. placebo | Qmax, Qave, irritative-IPSS, and IIEF better with VRF vs. placebo. |
| Regadas et al. [11] | 40 | Pdet-Qmax Qmax, IPSS | TMS + TDF vs. TMS + placebo | TMS + TDF reduces Pdet-Qmax without changing the maximum flow rate during micturition. |
| Tuncel et al. [12] | 60 | IPSS, Qmax, PRV, | SLF vs. TMS vs. TMS+ SLF | TMS + SLF is not superior to TMS in enhancing voiding symptoms. |
| Agenosov et al. [13] | 60 | IPSS, QoL | TMS vs. TMS + TDF vs. TDF | Significant increase in QoL with TMS + TDF. |
| Ye et al. [14] | 126 | IPSS, IIEF-5 | TMS + TDF vs. TMS vs. placebo | Both TMS + TDF and TMS alone had similar improvement in IPSS storage symptoms and IIEF-5. |
| Singh et al. [15] | 133 | IPSS, IPSS- QoL index, Qmax, and PVR, IIEF-5 | TMS vs. TMS + TDF vs. TDF | Monotherapy with either TMS or TDF showed similar results in efficacy endpoints with TMS + TDF. |
| Abdelrazek et al. [16] | 308 | Qmax, IPSS, PVR, IIEF | TDF vs. SDS vs. TDF + SDS | Qmax, IPSS, PVR, and IIEF scores improved significantly more with the combination than with either drug alone. |
| Tawfik et al. [17] | 258 | IPSS, IPSS- QoL index, Qmax, Qave, IIEF | TMS + FNS vs. TDF + FNS | Both groups had significant IPSS changes. TMS + FNS had better Qave. Qmax was comparable in both groups at the 12th week. All IIEF domains were significantly lowered in the TMS + FNS group. TDF + FNS showed a significant increase in IIEF-erectile function scores. |
| Casabé et al. [18] | 695 | IPSS, IIEF-5 | FNS +placebo vs TDF + FNS | TDF + FNS coadministration improves IPSS, and IIEF-5 in men who have comorbid erectile dysfunction. |
| Kosilov et al. [19] | 285 | IPSS, OABq, IIEF, MSHQ-EjD | DTS + SDS + TDL 0.5 + 2.5 + 2.5 vs. 0.5 + 5 + 5 vs. 0.5 + 10 + 20 | The 0.5 + 10 + 20 Group had significant improvement in OABq after the fourth week of the study. |
| Gotoh et al. [20] | 44 | IPSS, QoL, NTUF, NTMVVOABSS, SHIM | TDF as add-on to DTS | IPSS, QoL, NTUF, NTMVV improved significantly at 4 weeks OABSS, SHIM improved at 12 weeks Qmax, PVR showed no improvement. |
| Yamanishi et al. [21] | 24 | OABSS, NTUF, NIH-CPSI, MC | TDF + MGB vs. TDF | Changes from baseline in OABSS, NTUF, NIH-CPSI, MC were significantly reduced in combination therapy. |
(IPSS) International Prostate Symptom Score; (IPSS-QoL) IPSS Quality of Life; (Qmax) maximum flow rate; (Qave) average flow rate; (PVR); post-void residual volume; (IIEF-5) International Index of Erectile Function; (IIEF-EF) International Index of Erectile Function-Erectile Function Domain; (GAQ) Global Assessment Quality; (OABSS) Overactive bladder symptom score; (SHIM) sexual health inventory for men; (MSHQ-EjDQ) Male Sexual Health Questionnaire Ejaculatory Dysfunction; (OABq) Overactive Bladder Questionnaire; (NTUF) night-time urinary frequency; (NTMVV) night-time maximum voided volume; (MC) micturition chart; (TMS) tamsulosin; (TDF) tadalafil; (VRF) vardenafil; (SLD) Sildenafil; (SDS) Silodosin; (DTS) Dutasteride; (FNS) Finasteride; (MGB) mirabegron.